Acetium results in international meeting for Gastroenterology – excellent results on Acetium capsule repeated in Sweden
Biohit Oyj Press Release May 5,2014 at 3:30 local time (EEST)
Research results on Acetium capsule, invented and patented by Biohit Oyj, have been replicated and confirmed in Sweden. The results were presented in the major international meeting for gastroenterologists (Digestive Disease Week) in Chicago on May 3, 2014.
Researchers at Uppsala University (Sweden) showed in collaboration with Finnish researchers that Acetium capsule eliminates 68 % (max. 87 %) of carcinogenic acetaldehyde formed from alcohol into the gastric juice (Hellström et al). The study also demonstrated that slowly from Acetium® capsule releasing l-cysteine stays active in the stomach almost for 3 hours. Harmless binding product of L-cysteine and acetaldehyde stayed in the stomach for 3 hours as well. Every patient participating to the study had acid free stomach that was confirmed by biopsy and Biohit’s Gastro-Panel test.
Slowly L-cysteine releasing capsule formulation in prevention of gastric carcinogenesis associated with atrophic gastritis.
Per M. Hellström1, Panu Hendolin2, Pertti Kaihovaara3, Leif Kronberg4, Axel Meierjohann4, Anders Millerhovf5, Lea Paloheimo6, Heidi Sundelin4, Kari Syrjänen2, Dominic-Luc Webb1, and Mikko Salaspuro3
1Department of Medical Sciences, Uppsala University, Sweden, 2Biohit Oyj, Helsinki, Finland, 3Research Unit on Acetaldehyde and Cancer, University of Helsinki, Finland, 4Laboratory of Organic Chemistry, Åbo Akademi University, Turku, Finland, 5Clinical Trial Consultations, Uppsala, Sweden
Professor Per Hellström: ‘Marked amounts of carcinogenic acetaldehyde is formed also in low alcohol concentrations, therefore widely used food stuffs and so called non-alcoholic beverages containing from 1-5% alcohol form a substantial source for carcinogenic acetaldehyde. For instance widely used soy sauces contain from 1,5-5% alcohol.’
Professor Leif Kronberg: ‘The rather high levels of the binding product of acetaldehyde and l-cysteine in the gastric juice indicate that acetaldehyde formation in acid free stomach is much more active than expected.’
CEO Semi Korpela, Biohit Oyj: This confirms that Acetium® capsules by Biohit produced sufficiently and long enough the acetaldehyde-binding L-cysteine to gastric fluid .’
Attachment: Additional information on Acetium capsule
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com